3.19
0.04 (1.27%)
| Previous Close | 3.15 |
| Open | 3.20 |
| Volume | 250,691 |
| Avg. Volume (3M) | 304,589 |
| Market Cap | 172,116,720 |
| Price / Sales | 34.67 |
| Price / Book | 490.17 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Operating Margin (TTM) | -2,179.84% |
| Diluted EPS (TTM) | -1.77 |
| Quarterly Revenue Growth (YOY) | 40.00% |
| Total Debt/Equity (MRQ) | 97.55% |
| Current Ratio (MRQ) | 3.35 |
| Operating Cash Flow (TTM) | -54.06 M |
| Levered Free Cash Flow (TTM) | -28.16 M |
| Return on Assets (TTM) | -60.70% |
| Return on Equity (TTM) | -179.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Orchestra BioMed Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.81% |
| % Held by Institutions | 49.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2025 | 455,128 |
| Knott David M Jr | 30 Jun 2025 | 100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Chardan Capital, 526.96%) | Buy |
| Median | 15.00 (370.22%) | |
| Low | 10.00 (HC Wainwright & Co., 213.48%) | Buy |
| Average | 15.00 (370.22%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Sep 2025 | 10.00 (213.48%) | Buy | 2.74 |
| Chardan Capital | 13 Aug 2025 | 20.00 (526.96%) | Buy | 2.66 |
| 07 Aug 2025 | 20.00 (526.96%) | Buy | 2.60 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |